Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Recent evidence suggests that many malignancies, including breast cancer, are driven by a cellular subcomponent that displays stem cell-like properties. The protein phosphatase and tensin homolog (PTEN) is inactivated in a wide range of human cancers, an alteration that is associated with a poor prognosis. Because PTEN has been reported to play a role in the maintenance of embryonic and tissue-specific stem cells, we investigated the role of the PTEN/Akt pathway in the regulation of normal and malignant mammary stem/progenitor cell populations. We demonstrate that activation of this pathway, via PTEN knockdown, enriches for normal and malignant human mammary stem/progenitor cells in vitro and in vivo. Knockdown of PTEN in normal human mammary epithelial cells enriches for the stem/progenitor cell compartment, generating atypical hyperplastic lesions in humanized NOD/SCID mice. Akt-driven stem/progenitor cell enrichment is mediated by activation of the Wnt/beta-catenin pathway through the phosphorylation of GSK3-beta. In contrast to chemotherapy, the Akt inhibitor perifosine is able to target the tumorigenic cell population in breast tumor xenografts. These studies demonstrate an important role for the PTEN/PI3-K/Akt/beta-catenin pathway in the regulation of normal and malignant stem/progenitor cell populations and suggest that agents that inhibit this pathway are able to effectively target tumorigenic breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Knockdown of PTEN in normal mammary epithelial cells implanted into humanized mouse fat pads resulted in disorganized, hyperplastic lesions (44).”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [44]
In the citing paper
“These outgrowths displayed increased basal markers (smooth muscle actin, CK5, CK6) and decreased luminal markers (estrogen receptor, CK18), similar to our findings with mislocalization of SCRIB.”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012 · cited 8×
“Mammary tissue from reduction mammoplasties was dissociated as previously described [19].”
BackgroundMethodInfluentialSelf-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188 · cited 1×
“screened 38 breast cancer cell lines including MCF7 for various pathways and found that MCF7 cells displayed significantly low levels of the PI3/Akt activation when compared with other cell lines [52].”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“loop [43–46].”
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
Dontu, G., Abdallah, W. M., Foley, J. M., Jackson, K. W., Clarke, M. F., Kawamura, M. J., & Wicha, M. S. (2003) · Genes & Development · doi:10.1101/gad.1061803 · Cited by 2,406 · cited 2×
“Mammosphere cultures were grown in a serum-free mammary epithelium basal medium as previously described [18].”
BackgroundMethodSelf-citationSato, N., Meijer, L., Skaltsounis, L., Greengard, P., & Brivanlou, A. H. (2004) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,109 · cited 1×
“To examine the role of Wnt/b-catenin signaling, we used the GSK3-b inhibitor 6-bromoindirubin-39-oxime (Bio), which has been shown to be able to maintain pluripotency of human and mouse embryonic stem cells through activation of bcatenin signaling [30].”
MethodNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 2×
“therapeutic agents and relapse following initial treatment [7,8].”
BackgroundInfluentialIntrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794 · cited 1×
“Recent evidence utilizing in vitro systems [56], animal models [13], and clinical trials have suggested that breast cancer stem cells are relatively resistant to both radiation and chemotherapy [57].”
BackgroundBerns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Purification and unique properties of mammary epithelial stem cells
Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., Li, H. I., & Eaves, C. J. (2006) · Nature · doi:10.1038/nature04496 · Cited by 1,559 · cited 1×
“Furthermore, recent studies have shown that mammary stem cells are not contained within the SP population [47].”
BackgroundPten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516 · cited 2×
“heterozygous mice developing tumors in several organs including the breast [5,34].”
Background
Cited by
Items 301–400 of 532
Wu, N., Zhang, J., Zhao, J., Mu, K., Zhang, J., Jin, Z., Yu, J., & Liu, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9290 · Cited by 41
Breast Cancer Stem Cells: We've Got Them Surrounded
Körkaya, H., & Wicha, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3450 · Cited by 29
Self-citationChang, H., Wang, H., Chen, C.-Y., Hung, T.-W., Hou, M., Yuan, S. F., Huang, C., & Tseng, C. (2014) · Molecules · doi:10.3390/molecules19033149 · Cited by 34
“Most types of cancer, including breast cancer, originate from a small population of cancer stem cells (CSCs) [1–4].”
Rappa, G., Fargeas, C. A., Le, T. T., Corbeil, D., & Lorico, A. (2015) · Stem Cells · doi:10.1002/stem.1953 · Cited by 29
Song, Z., Han, X., Shen, L., Zou, H., Zhang, B., Liu, J., & Gong, A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.001 · Cited by 30
French, R., Hayward, O. A., Jones, S., Yang, W. W., & Clarkson, R. W. E. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0478-y · Cited by 29
“has the added potential to impact negatively on the maintenance of bCSCs [30, 44].”
BackgroundMethodNatural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Erkısa, M., Sarıman, M., Geyik, Ö. G., Geyik, C., Stanojković, T., & Ulukaya, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210628131409 · Cited by 28
Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 32
Timmermans‐Sprang, E. P. M., Gracanin, A., & Mol, J. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1544-y · Cited by 31
“In human breast cancer, loss of PTEN is associated with activation of the PI3K/AKT Pathway [12], which may result in increased nuclear stabilization of β-Catenin in mammary stem cells using human breast tissue xenografts [37].”
BackgroundIyer, S., Viernes, D. R., Chisholm, J. D., Margulies, B. S., & Kerr, W. G. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0122 · Cited by 28
“A recurring theme in several stem cell types is for the PI3K/Akt pathway to inactivate GSK3b thus promoting activation and nuclear translocation of b-catenin [76,77].”
BackgroundNon-coding RNAs Functioning in Colorectal Cancer Stem Cells
Fanale, D., Barraco, N., Listì, A., Bazan, V., & Russo, A. D. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42059-2_5 · Cited by 26
Yin, W., Pham, C. V., Wang, T., Shamaileh, H. A., Chowdhury, R., Patel, S., Li, Y., Kong, L., Hou, Y., Zhu, Y., et al. (2022) · Biomolecules · doi:10.3390/biom12111623 · Cited by 26
Chiche, A., Moumen, M., Romagnoli, M., Petit, V., Lasla, H., Jézéquel, P., de la Grange, P., Jonkers, J., Deugnier, M., Glukhova, M. A., et al. (2016) · Oncogene · doi:10.1038/onc.2016.396 · Cited by 26
Andrews, A., Warner, K. A., Rodriguez-Ramirez, C., Pearson, A. T., Nör, F., Zhang, Z., Kerk, S. A., Kulkarni, A., Helman, J. I., Brenner, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2730 · Cited by 26
Self-citationZhu, N., Wang, Q. H., Wu, Z., Wang, Y., Zeng, M., & Yuan, Y. (2022) · Journal of Virology · doi:10.1128/jvi.01941-21 · Cited by 28
“Activation of PI3K/mTOR enriched CSCs in breast cancer (54) and blockage of PI3K/ mTOR signaling by dual inhibitor VS-5584 preferentially inhibits proliferation and sur-”
BackgroundChallenges in the development of future treatments for breast cancer stem cells
Patel (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s8293 · Cited by 30
Nanotechniques Inactivate Cancer Stem Cells
Goltsev, А., Babenko, N. N., Gaevska, Y., Bondarovich, N. A., Дубрава, Т. Г., Ostankov, M. V., Chelombitko, O. V., Malyukin, Y. V., Klochkov, V., & Kavok, N. S. (2017) · Nanoscale Research Letters · doi:10.1186/s11671-017-2175-9 · Cited by 25
“The emerging set of HA-CD44 activates many receptor tyrosine kinases, resulting in activation of PI3K/Akt/ mTOR way [32, 33], which plays the role of a single universal signal transmission mechanism to the translation apparatus and is responsible for the integration of proliferative stimuli.”
BackgroundSun, M., He, X., Huang, P.-Y., Qi, Q., Sun, W., Liu, G.-S., & Hua, J. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i38.5822 · Cited by 26
Chen, Y., Wang, Y., Qiu, K., Cao, Y., Zhang, F., Zhao, H., & Liu, X. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1393 · Cited by 24
ERBB Signaling Pathway in Cancer Stem Cells
Hassan, G., & Seno, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-12974-2_3 · Cited by 26
Kim, R., Bae, E., Hong, Y. K., Hong, J. Y., Kim, N. K., Ahn, H. J., Oh, J. J., & Park, D. S. (2014) · Oncology · doi:10.1159/000363186 · Cited by 24
Heitmeir, B., Deniz, M., Janni, W., Rack, B. K., Schochter, F., & Wiesmüller, L. (2022) · Cancers · doi:10.3390/cancers14040997 · Cited by 23
“Interplay between Stemness, EMT and DNA Damage Response Pathways in CTCs To permit fast morphological and functional changes, CTCs adopt hybrid states with high plasticity between epithelial (e.g., EpCAM, E-Cadherin) and mesenchymal (e.g., SLUG, SNAIL) characteristics [62,156,168].”
BackgroundInfluentialSzymczak-Pajor, I., Drzewoski, J., Świderska, E., Strycharz, J., Gabryanczyk, A., Kasznicki, J., Bogdańska, M., & Śliwińska, A. (2023) · Pharmaceuticals · doi:10.3390/ph16010115 · Cited by 26
A Cancer Stem Cell Potent Cobalt(III)–Cyclam Complex Bearing Two Tolfenamic Acid Moieties
Cressey, P., Eskandari, A., & Suntharalingam, K. (2017) · Inorganics · doi:10.3390/inorganics5010012 · Cited by 23
Targeting Cancer Stem Cells with Defined Compounds and Drugs
Naujokata, C., & Laufer, S. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.01.7 · Cited by 27
“de Notch signaling pathways [20-25], expression and activation of the Akt/PKB and ATR/CHK1 survival pathways [26-28], aberrant PI3K/Akt/mTOR-mediated signaling and loss of phosphatase and tensin homolog (PTEN) [29-31], amplified activity of aldehyde dehydrogenase 1 (ALDH1) [32-35], amplified checkpoint activation and…”
BackgroundAnticancer properties of carotenoids in prostate cancer. A review.
Soares, N. D. C. P., Teodoro, A. J., Falagan-Lotsch, P., Granjeiro, J. M., & Borojević, R. (2015) · PubMed · doi:10.14670/hh-11-635 · Cited by 30
“Furthermore, the PI3K/Akt pathway is important in regulating the mammary stem/progenitor cells by promoting β-catenin downstream events through the phosphorylation of glycogen synthase kinase 3β (GSK3β) (Korkaya et al., 2009).”
BackgroundFani, S., Dehghan, F., Karimian, H., Lo, K. M., Nigjeh, S. E., Yeap, S. K., Soori, R., Chow, K. M., Kamalıdehghan, B., Ali, H. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160836 · Cited by 23
“The Wnt/β-catenin pathway plays a critical role in the mammary gland in terms of the self-renewal process of BCSCs [31].”
BackgroundInfluentialPI3 K/AKT/mTOR pathway and its role in breast cancer stem cells
Prabhu, K. S., Kuttikrishnan, S., Mariyam, Z., Habeeba, U., Panicker, A. J., Masoodi, T., Junejo, K., & Shahab Uddin, M. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04297-3 · Cited by 28
Saoncella, S., Tassone, B., Deklic, E., Avolio, F., Jon, C., Tornillo, G., Luca, E. D., Iorio, E. D., Piva, R., Cabodi, S., et al. (2013) · Stem Cells · doi:10.1002/stem.1565 · Cited by 24
Targeting breast cancer stem cells
Wicha, M. S. (2009) · The Breast · doi:10.1016/s0960-9776(09)70274-7 · Cited by 22
Self-citationPharmacological targets of breast cancer stem cells: a review
Pindiprolu, S. K. S. S., Krishnamurthy, P. T., & Chintamaneni, P. K. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1479-3 · Cited by 24
Recent Advances in Targeted Nanotherapeutic Approaches for Breast Cancer Management
Gupta, P., Neupane, Y. R., Parvez, S., & Kohli, K. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0281 · Cited by 26
Slug/β-Catenin–Dependent Proinflammatory Phenotype in Hypoxic Breast Cancer Stem Cells
Storci, G., Bertoni, S., Carolis, S. D., Papi, A., Nati, M., Ceccarelli, C., Pirazzini, C., Garagnani, P., Ferrarini, A., Buson, G., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.020 · Cited by 22
Ali, K., Nabeel, M., Mohsin, F., Iqtedar, M., Islam, M. F., Rasool, M. F., Hashmi, F. K., Hussain, S. A., & Saeed, H. (2024) · Medical Oncology · doi:10.1007/s12032-024-02347-z · Cited by 24
Alcohol and Breast Cancer: Reconciling Epidemiological and Molecular Data
Zakhari, S., & Hoek, J. B. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-09614-8_2 · Cited by 21
“The role of aberrant Wnt signaling in breast carcinogenesis is further highlighted by the fi nding that knockdown of the tumor-suppressor gene PTEN ( phosphatase and tensin homolog deleted on chromosome 10 ) resulted in the activation of the Wnt/β-catenin pathway in human breast cells [ 12 ].”
BackgroundIstvánffy, R., Vilne, B., Schreck, C., Ruf, F., Pagel, C., Grziwok, S., Henkel, L., da Costa, O. P., Berndt, J., Stümpflen, V., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.09.018 · Cited by 24
Shin, D., Park, J., Lee, J., Won, H., Jang, K.-S., Min, K., Jang, S., Woo, J. K., Oh, S. H., & Kong, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3640 · Cited by 21
Shriver, M., Marimuthu, S., Paul, C. D., Geist, J., Seale, T. S., Κωνσταντόπουλος, Κ., & Kontrogianni‐Konstantopoulos, A. (2016) · Oncotarget · doi:10.18632/oncotarget.9985 · Cited by 21
“Accordingly, enhanced activation of the PI3K/AKT pathway in breast cancer cells has been correlated with increased mammosphere and tumor formation in vitro and in vivo, respectively, via phosphorylation and activation of the master transcriptional factor NF-κB, which in turn regulates the expression of several genes i…”
BackgroundHER2 in stemness and epithelial–mesenchymal plasticity of breast cancer
Voutsadakis, I. A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1961-x · Cited by 23
Sundram, V., Ganju, A., Hughes, J. E., Khan, S., Chauhan, S. C., & Jaggi, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2277 · Cited by 20
“Studies have identified that inhibitors of the PTEN/ Akt/GSK3β signaling cascade and regulation of β-catenin act as potential agents to effectively target cancer stem cells and tumorigenic cancer cells [3, 4].”
BackgroundLu, Y., Cheng, F., & Teng, L. (2016) · Scientific Reports · doi:10.1038/srep32723 · Cited by 20
Ni, C., Yang, Q., Zhang, J., Liu, Y., Xu, J., Hu, H., Wu, Q., Wu, Q., Wang, Y., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12822 · Cited by 20
“It would be more definitive to assess the ability of residual cancer stem cells to initiate tumors upon secondary implantation in NOD/ SCID mice [21, 37].”
BackgroundLoss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells
Li, D., Mullinax, J. E., Aiken, T. J., Xin, H., Wiegand, G. W., Anderson, A., Thorgeirsson, S. S., Avital, I., & Rudloff, U. (2018) · BMC Cancer · doi:10.1186/s12885-018-4690-1 · Cited by 20
TRIP6 enhances stemness property of breast cancer cells through activation of Wnt/β-catenin
Zhao, X., Jiang, C., Xu, R., Liu, Q., Liu, G., & Zhang, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1136-z · Cited by 20
Wang, X., Li, X., Fu, X., Bai, M., Li, X., Mei, Q., Nie, J., Wu, Z., & Han, W. (2015) · Current Protein and Peptide Science · doi:10.2174/138920371604150429151457 · Cited by 20
Tissue Factor promotes breast cancer stem cell activity in vitro
Shaker, H., Harrison, H., Clarke, R. B., Landberg, G., Bundred, N. J., Versteeg, H. H., & Kirwan, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13928 · Cited by 22
Zhao, Q., Parris, A. B., Howard, E. W., Zhao, M., Ma, Z., Guo, Z., Xing, Y., & Yang, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-11751-7 · Cited by 24
Sumkhemthong, S., Chamni, S., Ecoy, G. A. U., Taweecheep, P., Suwanborirux, K., Prompetchara, E., Pithi Chanvorachote, B., & Chaotham, C. (2021) · Marine Drugs · doi:10.3390/md19050261 · Cited by 19
“The downregulation of stemness transcription factors is mediated through the Akt/GSK-3β/β-catenin cascade [24], which correlates with the suppressive effect of jorunnamycin A on these key proteins in the CSC-enriched spheroids obtained from H460 cells (Figure 3D).”
BackgroundMethodInfluentialWIP-YAP/TAZ as A New Pro-Oncogenic Pathway in Glioma
Rivas-Muñoz, S., Antón, I. M., & Wandosell, F. G. (2018) · Cancers · doi:10.3390/cancers10060191 · Cited by 19
“As previously mentioned, one of the most commonly-modified pathways in gliomas is PI3K-PTEN-Akt, which is activated in normal and cancer cells [58] and controls tumour cell proliferation [59,60] and/or maintenance of the tumour phenotype [61].”
BackgroundHao, Q., Wang, P., Dutta, P., CHUNG, S. S., Li, Q., Wang, K., Li, J., Cao, W., Deng, W., Geng, Q., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03235-w · Cited by 19
The PTEN and Myotubularin Phosphoinositide 3-Phosphatases: Linking Lipid Signalling to Human Disease
Davies, E. M., Sheffield, D. A., Tibarewal, P., Fedele, C. G., Mitchell, C. A., & Leslie, N. R. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-3012-0_8 · Cited by 19
Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review
Guo, S., Zheng, S., Liu, M., & Wang, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081024 · Cited by 18
Dolatshad, N. F., Hellen, N., Jabbour, R. J., Harding, S. E., & Földes, G. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00076 · Cited by 20
R-spondin3 Is Associated with Basal-Progenitor Behavior in Normal and Tumor Mammary Cells
Tocci, J. M., Felcher, C. M., Solá, M. E. G., Goddio, M. V., Zimberlin, M. N., Rubinstein, N., Srebrow, A., Coso, O. A., Abba, M. C., Meiss, R. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2676 · Cited by 18
Siddharth, S., Mohapatra, P., Preet, R., Das, D., Satapathy, S. R., Choudhuri, T., & Kundu, C. N. (2013) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13786659070190 · Cited by 17
Zhou, J., Zhang, C., Zheng, G., & Qiu, Z. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/8478943 · Cited by 17
“Moreover, canonical Wnt/β-catenin signaling which is featured by the accumulation of β-catenin and the elevated transcription of downstream oncotargets (c-Myc and cyclin D1) can be mediated by PI3K/Akt crosstalk [9].”
BackgroundRusso, A., Colina, J. A., Moy, J., Baligod, S., Czarnecki, A. A., Varughese, P., Lantvit, D. D., Dean, M., & Burdette, J. E. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03663-2 · Cited by 18
Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation
Zhan, J., Wu, L., Chen, L., Yuan, Y., Xie, G., Sun, A.-M., Liu, Y., & Chen, Z.-X. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0020-1 · Cited by 17
Akt–Oct4 regulatory circuit in pluripotent stem cells
Su, T., Dan, S., & Wang, Y. (2014) · Chinese Science Bulletin · doi:10.1007/s11434-014-0131-y · Cited by 17
DeGuo, L., Ma, Y.-M., Zhu, A.-J., & Han, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.13125 · Cited by 19
“The activation of the Wnt/β-catenin pathway was observed following knockdown of the tumor suppressor gene phosphatase and tensin homolog (PTEN) in human breast cells [27].”
BackgroundGao, F., Liu, S., Wang, J., Wei, G., Yu, C., Zheng, L., Sun, L., Wang, G., Sun, Y., Bao, Y., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03118-4 · Cited by 20
Su, Y., Shankar, K., Rahal, O. M., & Simmen, R. C. M. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.09.008 · Cited by 18
“elaborated linkage between these two signaling pathways in the regulation of normal and malignant mammary stem/progenitor cells in vivo and in vitro [55].”
BackgroundPTEN is required to maintain luminal epithelial homeostasis and integrity in the adult mammary gland
Shore, A. N., Chang, C.-H., Kwon, O.-J., Weston, M. C., Zhang, M., Xin, L., & Rosen, J. M. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2015.10.023 · Cited by 15
“…is associated with hormone receptor-negative breast cancer (Saal et al., 2005), and in vitro studies using human and mouse mammary epithelial 3D culture models have shown that depletion of PTEN leads to a reduction in hormone receptor-positive cells (Ghosh et al., 2013; Korkaya et al., 2009).”
InfluentialNatural Products That Target Cancer Stem Cells
Singh, D., Pandey, H., & Singh, V. K. (2022) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-9258-8.ch008 · Cited by 15
Pradhan, T., Kumar, V., Hermon, E. S., Krishna, R., John, S., Jissa, V. T., Anjana, S., Chandramohan, K. N., & Nair, S. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.581671 · Cited by 15
“Reiteratively, AKT is known to regulate b-catenin stabilization (40, 41).”
BackgroundMycochemicals against Cancer Stem Cells
Tacchini, M., Sacchetti, G., Guerrini, A., & Paganetto, G. (2023) · Toxins · doi:10.3390/toxins15060360 · Cited by 16
Phenotypic Screening Reveals Topoisomerase I as a Breast Cancer Stem Cell Therapeutic Target
Zhang, F., Rothermund, K. D., Gangadharan, S. B., Pommier, Y. G., Prochownik, E. V., & Lazo, J. S. (2012) · Oncotarget · doi:10.18632/oncotarget.632 · Cited by 15
“com/oncotarget IL-8 [19].”
The mechanisms of class 1A PI3K and Wnt/β-catenin coupled signaling in breast cancer
Rodgers, S. J., Mitchell, C. A., & Ooms, L. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220866 · Cited by 16
A Phenotypic Mouse Model of Basaloid Breast Tumors
Kim, S., Roopra, A., & Alexander, C. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030979 · Cited by 14
Zhou, E., Song, X., Li, B.-Y., & Wu, F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s77828 · Cited by 14
Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion
Arianfar, E., Shahgordi, S., & Memarian, A. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1845670 · Cited by 16
Wang, C., Mao, F., Zhang, M., Li, W., Guan, H., Sun, Y., Xie, S., & Zhong, X. (2013) · Neuropathology · doi:10.1111/neup.12041 · Cited by 14
“A number of studies have reported that the Wnt/b-catenin pathway is mainly involved,(28,30,31) while others underscore the importance of the PI3K/AKT pathway.(12,31) One study has demonstrated a significant correlation between high b-catenin levels and low PTEN levels,(32) which is consistent with our results.”
BackgroundResultChen, J., Ko, J., Kim, J. T., Cho, J. S., Qiu, S., Kim, G.-D., Auh, J., & Lee, H. J. (2019) · Food & Function · doi:10.1039/c9fo00009g · Cited by 14
Franco, S. D., Mancuso, P., Benfante, A., Spina, M., Iovino, F., Dieli, F., Stassi, G., & Todaro, M. (2011) · Cancers · doi:10.3390/cancers3021957 · Cited by 15
“[47] showed that the increased activity of Wnt/β-catenin was mediated by activation of Akt signaling activation.”
BackgroundXu, R., Sun, Y., Tian, F., & Zhao, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-98578-9 · Cited by 13
Xiong, J., Zhang, T., Lan, P., Zhang, S., & Fu, L. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.11 · Cited by 13
Chemische Kontrolle des Schicksals und Entwicklungspotenzials von Stammzellen
Lyssiotis, C. A., Lairson, L. L., Boitano, A. E., Wurdak, H., Zhu, S., & Schultz, P. G. (2010) · Angewandte Chemie · doi:10.1002/ange.201004284 · Cited by 13
MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells
Kim, S., Jeon, M., Lee, J. E., & Nam, S. J. (2016) · Oncology Reports · doi:10.3892/or.2016.4557 · Cited by 13
Insulin regulates human mammosphere development and function
Watt, A. P., Lefèvre, C. M., Wong, C. S., Nicholas, K. R., & Sharp, J. A. (2021) · Cell and Tissue Research · doi:10.1007/s00441-020-03360-0 · Cited by 13
Chemopreventive and Therapeutic Potential of Phytochemicals Targeting Cancer Stem Cells
Kim, D., & Surh, Y. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0035-9 · Cited by 14
Metastasis of Colorectal Cancer
Beauchemin, N., & Huot, J. (2010) · Cancer metastasis · doi:10.1007/978-90-481-8833-8 · Cited by 16
Li, Q., Li, Y., Gu, B., Fang, L., Zhou, P., Bao, S., Huang, L., & Dai, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.639419 · Cited by 13
Therapeutic Implications of Cytokines and Chemokines Network in Cancer
Mir, M. A., Jan, N., & Noor, I. (2023) · Springer eBooks · doi:10.1007/978-981-99-4657-0_14 · Cited by 10
Miller, J. L., Kanke, M., Rauner, G., Bakhle, K. M., Sethupathy, P., & de Walle, G. R. V. (2022) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-022-09525-7 · Cited by 12
Wang, N., Dong, B., Quan, Y., Chen, Q., Chu, M., Xu, J., Xue, W., Huang, Y., Yang, R., & Gao, W. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.007 · Cited by 12
“Continuous activation of AKT through the knockout of protein phosphatase and tensin homolog (PTEN) leads to increased epithelial progenitor cells in the prostate gland (Mulholland et al., 2009; Wang et al., 2006a) and the mammary gland (Korkaya et al., 2009).”
Khan, I., Ansari, I. A., Singh, P., Dass, J. F. P., & Khan, F. (2017) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-017-0818-1 · Cited by 12
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Zhang, P., Chen, Y., Gong, M., Zhuang, Z., Wang, Y., Mu, L., Wang, T., Pan, J., Liu, Y., Xu, J., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493957 · Cited by 12
Targeted therapies of metastatic breast cancer: Relationships with cancer stem cells
Ferrari, P., Nicolini, A., & Carpi, A. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.03.006 · Cited by 13
Lahiri, A., Vundavilli, H., Mondal, M., Bhattacharjee, P., Decker, B., Priore, G. D., Reeves, N. P., & Datta, A. A. (2023) · IEEE Access · doi:10.1109/access.2023.3283291 · Cited by 11
mTOR Inhibition Abrogates Human Mammary Stem Cells and Early Breast Cancer Progression Markers
Bouamar, H., Broome, L. E., Lathrop, K. I., Jatoi, I., Brenner, A. J., Nazarullah, A. N., Gorena, K. M., Garcia, M., Chen, Y., Kaklamani, V., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-023-01727-z · Cited by 14
“Further conflicts in other models include the use of mTOR inhibitors in mouse strains, which showed no ability in preventing mammosphere formation [46].”
BackgroundMolecular Mechanisms Underlying Breast Cancer and Role of Plant Products in Targeted Therapy
Singhal, S., Singh, M., Singh, R. K., Tiwari, V. K., & Bajpai, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821277-6.00011-8 · Cited by 16
Cytotoxicity of curcumin against CD44± prostate cancer cells: Roles of miR-383 and miR-708Preprint
Panahizadeh, R., Vatankhah, M. A., Jeddi, F., Arabzadeh, A., Nejati‐Koshki, K., & Najafzadeh, N. (2022) · Research Square · doi:10.21203/rs.3.rs-1281066/v1 · Cited by 11
Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells
Vasileiou, M., Diamantoudis, S. C., Tsianava, C., & Nguyen, N. P. (2024) · Current Oncology · doi:10.3390/curroncol31060232 · Cited by 11
“The PI3K/Akt/NF-κ B pathway has shown positive outcomes in BCSC-based therapies, especially for HER-2 positive cancers, with researchers reporting reduced tumor growth and metastasis, which result in improved patient outcomes [156].”
BackgroundGao, W., Guo, N., Yan, H., Zhao, S., Sun, Y., & Chen, Z. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03748-8 · Cited by 11
Cardiff, R. D., Couto, S. S., & Bolon, B. N. (2011) · Breast Cancer Research · doi:10.1186/bcr2887 · Cited by 10
“For example, the populations of both normal stem cells and CSC are characterized by phosphatidylinositol 3-kinase activation resulting from HER2 amplifi cation [96] in conjunction with decreased PTEN expression and decreased canonical Wnt/β-catenin interactions [97].”
BackgroundWang, Q., Mao, Z., Liu, Z., Xu, M., Huang, S., Wang, Y., Xu, Y., Qi, L., Liu, M., & Liu, Y. (2022) · Communications Biology · doi:10.1038/s42003-022-04004-5 · Cited by 10
Sawah, E. A., Chen, X., Marchion, D. C., Xiong, Y., Ramirez, I. J., Abbasi, F., Zgheib, N. B., Chon, H. S., Wenham, R. M., Apte, S. M., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.088 · Cited by 10
“0864 proliferative activity in vitro in several human tumor cells, including malignant pleural mesothelioma [14], human multiple myeloma [15], prostate cancer [7,16], breast cancer [17,18], OVCA [8,9,19], and head and neck squamous cancer cells [20].”
BackgroundRahal, O. M., Machado, H. L., Montales, M. T. E., Pabona, J. M. P., Heard, M. E., Nagarajan, S., & Simmen, R. C. M. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.08.006 · Cited by 10
“…by Wnt, Notch, Hedgehog, and phosphatidylinositol 3-kinase/Akt have been identified as critical for growth control of normal MaSC and when de-regulated, may underlie aberrant CSC self-renewal and multidifferentiation (Li et al., 2003; Liu et al., 2006; Farnie & Clarke, 2007; Korkaya et al., 2009).”
BackgroundGupta, S., Sharma, P., Chaudhary, M., Premraj, S., Kaur, S. J., Vijayan, V., Arun, M. G., Prasad, N. G., & Ramachandran, R. (2022) · Glia · doi:10.1002/glia.24270 · Cited by 10
Ma, X., Zhang, Y., Kang, Y., Li, L., & Zheng, W. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.08.066 · Cited by 9
Metadata
- Authors
- Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S.
- Affiliations
- University of Michigan (US)
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-06-02
- Volume
- 7
- Issue
- 6
- Pages
- e1000121
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2683567
- OpenAlex
- W2009094422
- Cited by
- 523
- References
- 58
- Citations by year
- 2025: 8 · 2024: 11 · 2023: 16 · 2022: 21 · 2021: 21 · 2020: 23 · 2019: 21 · 2018: 21 · 2017: 23 · 2016: 39 · 2015: 59 · 2014: 42 · 2013: 65 · 2012: 64
- FWCI
- 25.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- University of Michigan
- A. Alfred Taubman Medical Research Institute
- National Institutes of Health (CA46592)
- School of Medicine, Stanford University
- National Cancer Institute (CA101860, 5P30 CA 46592, R01CA129765, CA129765, R01CA101860, P30CA046592)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Keywords
- mammary stem/progenitor cells, PTEN, Akt signaling, Wnt/β-catenin signaling, breast cancer, perifosine, PI3K/Akt signaling, atypical hyperplasia, breast tumor xenografts, cancer stem cells
- MeSH terms
- Animals, Breast, Breast Neoplasms, Female, Gene Expression Regulation, Humans, Mammary Glands, Animal, Stem Cells, Neoplastic Stem Cells, Signal Transduction, Mice, SCID, Mice, Inbred NOD, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, beta Catenin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.